Black Diamond Therapeutics
BDTX
BDTX
74 hedge funds and large institutions have $209M invested in Black Diamond Therapeutics in 2023 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
74
Holders Change
+24
Holders Change %
+48%
% of All Funds
1.17%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
%
% of All Funds
0.03%
New
32
Increased
13
Reduced
16
Closed
8
Calls
$3.11M
Puts
$398K
Net Calls
+$2.72M
Net Calls Change
+$2.67M
Top Buyers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$13.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.1M |
| 3 |
DM
Deerfield Management
New York
|
+$9.09M |
| 4 |
RI
RTW Investments
New York
|
+$8.59M |
| 5 |
JPMorgan Chase & Co
New York
|
+$5.45M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.25M |
| 2 |
Millennium Management
New York
|
-$2.14M |
| 3 |
Two Sigma Advisers
New York
|
-$824K |
| 4 |
NM
Newtyn Management
New York
|
-$538K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$284K |
